SOD1 G93A

Superoxide dismutase 1 (SOD1) is an enzyme that normally protects cells by breaking down harmful reactive oxygen molecules. Mutations in SOD1 are the second most common genetic cause of amyotrophic lateral sclerosis (ALS) in European populations, accounting for a significant portion of familial cases [1]. The A4V variant analyzed here represents one of the most clinically severe SOD1 mutations, particularly prevalent in North American ALS patients, and has been definitively classified as pathogenic through multiple expert reviews with no conflicting evidence. Critically, this variant has never been observed in the gnomAD database of healthy individuals, strongly supporting its disease-causing role. The structural prediction for SOD1 A4V achieved an exceptionally high average confidence score of 97.8% (pLDDT), indicating that AlphaFold2 could model this protein structure with near-experimental quality. This high confidence across the entire structure suggests that the A4V mutation does not cause gross misfolding or structural collapse, but rather may introduce subtle changes that affect protein stability, metal binding, or protein-protein interactions. Understanding these structural details is crucial because misfolded SOD1 proteins form toxic aggregates in motor neurons, and recent research has demonstrated that these aggregates can spread through the nervous system in a prion-like manner, seeding further misfolding in neighboring cells [6]. The clinical significance of identifying SOD1 mutations has increased dramatically with the recent authorization of SOD1-targeted antisense oligonucleotide therapies like tofersen, which work by reducing the production of mutant SOD1 protein [1]. Real-world treatment outcomes show that tofersen can halt disease progression and even lead to functional improvements in some patients when administered early, with particularly encouraging results in genetically homogeneous populations [3][8]. These treatments are delivered via intrathecal injection directly into the cerebrospinal fluid, with optimized protocols now available for precise central nervous system targeting [2]. The rapid identification of SOD1 mutation carriers through genetic screening is therefore critical for enabling early therapeutic intervention. Beyond motor neuron degeneration, SOD1 mutations affect multiple body systems. Recent research has revealed that SOD1 alterations disrupt lipid metabolism and hypothalamic function, with measurable changes in blood triglyceride and cholesterol levels appearing in both symptomatic patients and pre-symptomatic carriers [4]. SOD1 also influences extracellular vesicle biology, which may contribute to how disease signals spread between cells [7]. While gastrointestinal dysfunction is commonly observed in ALS patients, studies in mouse models suggest this may be secondary to neurological damage rather than direct gut pathology [5]. The A4V variant's absence from healthy populations, combined with its pathogenic classification and the availability of targeted therapies, makes genetic testing and early identification particularly important for affected families.